{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:39:20Z","timestamp":1784770760444,"version":"3.55.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"15","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Excessively activated or dysregulated complement activation may contribute to the pathogenesis of a wide range of human diseases, thus leading to a surge in complement inhibitors. Herein, we developed a human-derived and antibody-like C3b-targeted fusion protein (CRIg-FH-Fc) x2, termed CG001, that could potently block all 3 complement pathways. Complement receptor of the immunoglobulin superfamily (CRIg) and factor H (FH) bind to distinct sites in C3b and synergistically inhibit complement activation. CRIg occupancy in C3b prevents the recruitment of C3 and C5 substrates, whereas FH occupancy in C3b accelerates the decay of C3\/C5 convertases and promotes the factor I\u2013mediated degradation and inactivation of C3b. CG001 also showed therapeutic effects in alternative pathways\u2013induced hemolytic mouse and classical pathways\u2013induced mesangial proliferative glomerulonephritis rat models. In the pharmacological\/toxicological evaluation in rats and cynomolgus monkeys, CG001 displayed an antibody-like pharmacokinetic profile, a convincing complement inhibitory effect, and no observable toxic effects. Therefore, CG001 holds substantial potential for human clinical studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012874","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T21:03:01Z","timestamp":1718226181000},"page":"4181-4193","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["CG001, a C3b-targeted complement inhibitor, blocks 3 complement pathways: development and preclinical evaluation"],"prefix":"10.1182","volume":"8","author":[{"given":"Ling","family":"Li","sequence":"first","affiliation":[{"name":"1Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Ding","sequence":"additional","affiliation":[{"name":"1Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Dong","sequence":"additional","affiliation":[{"name":"2Alphamab Co Ltd., Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shupei","family":"Shen","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Lv","sequence":"additional","affiliation":[{"name":"4ComGen Pharmaceutical Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7250-3526","authenticated-orcid":false,"given":"Jie","family":"Yu","sequence":"additional","affiliation":[{"name":"4ComGen Pharmaceutical Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luying","family":"Li","sequence":"additional","affiliation":[{"name":"4ComGen Pharmaceutical Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Chen","sequence":"additional","affiliation":[{"name":"1Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilin","family":"Wang","sequence":"additional","affiliation":[{"name":"2Alphamab Co Ltd., Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[{"name":"2Alphamab Co Ltd., Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Hu","sequence":"additional","affiliation":[{"name":"1Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"5Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"2024081315253455200_bib1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"issue":"1","key":"2024081315253455200_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41467-023-36068-0","article-title":"The classical pathway triggers pathogenic complement activation in membranous nephropathy","volume":"14","author":"Seifert","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"2024081315253455200_bib3","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41591-020-1021-2","article-title":"Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection","volume":"26","author":"Ramlall","year":"2020","journal-title":"Nat Med"},{"issue":"17","key":"2024081315253455200_bib4","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJM199010253231707","article-title":"Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria","volume":"323","author":"Yamashina","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024081315253455200_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.smim.2016.05.001","article-title":"Therapeutic complement inhibition in complement-mediated hemolytic anemias: past, present and future","volume":"28","author":"Risitano","year":"2016","journal-title":"Semin Immunol"},{"issue":"10424","key":"2024081315253455200_bib6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"2024081315253455200_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMra2201664","article-title":"Breakthrough hemolysis in PNH with proximal or terminal complement inhibition","volume":"387","author":"Notaro","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2024081315253455200_bib8","article-title":"Danicopan: first approval","author":"Kang","year":"2024","journal-title":"Drugs"},{"issue":"11","key":"2024081315253455200_bib9","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1096\/fj.14-258046","article-title":"A\u00a0novel CRIg-targeted complement inhibitor protects cells from complement damage","volume":"28","author":"Qiao","year":"2014","journal-title":"FASEB J"},{"issue":"12","key":"2024081315253455200_bib10","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.4049\/jimmunol.1800987","article-title":"Complement inhibitor CRIg\/FH ameliorates renal ischemia reperfusion injury via activation of PI3K\/AKT signaling","volume":"201","author":"Hu","year":"2018","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"2024081315253455200_bib11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1186\/s12882-019-1599-0","article-title":"The new complement inhibitor CRIg\/FH ameliorates lupus nephritis in lupus-prone MRL\/lpr mice","volume":"20","author":"Shi","year":"2019","journal-title":"BMC Nephrol"},{"key":"2024081315253455200_bib12","doi-asserted-by":"crossref","first-page":"746068","DOI":"10.3389\/fimmu.2022.746068","article-title":"A\u00a0targeted complement inhibitor CRIg\/FH protects against experimental autoimmune myasthenia gravis in rats via immune modulation","volume":"13","author":"Song","year":"2022","journal-title":"Front Immunol"},{"issue":"7116","key":"2024081315253455200_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature05263","article-title":"Structure of C3b in complex with CRIg gives insights into regulation of complement activation","volume":"444","author":"Wiesmann","year":"2006","journal-title":"Nature"},{"issue":"7","key":"2024081315253455200_bib14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/ni.1755","article-title":"Structure of complement fragment C3b-factor H and implications for host protection by complement regulators","volume":"10","author":"Wu","year":"2009","journal-title":"Nat Immunol"},{"issue":"3","key":"2024081315253455200_bib15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jmb.2013.10.039","article-title":"Structural determinants of unique properties of human IgG4-Fc","volume":"426","author":"Davies","year":"2014","journal-title":"J\u00a0Mol Biol"},{"issue":"1","key":"2024081315253455200_bib16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4049\/jimmunol.155.1.348","article-title":"Identification of complement regulatory domains in human factor H","volume":"155","author":"Gordon","year":"1995","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"2024081315253455200_bib17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1042\/bj2350723","article-title":"The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase","volume":"235","author":"Pangburn","year":"1986","journal-title":"Biochem J"},{"issue":"1","key":"2024081315253455200_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1084\/jem.146.1.257","article-title":"Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution","volume":"146","author":"Pangburn","year":"1977","journal-title":"J\u00a0Exp Med"},{"issue":"8","key":"2024081315253455200_bib19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0161-5890(83)90076-7","article-title":"Interaction of C3 and C3b with immunoglobulin G","volume":"20","author":"Kulics","year":"1983","journal-title":"Mol Immunol"},{"issue":"1","key":"2024081315253455200_bib20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-017-0496-x","article-title":"Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes","volume":"10","author":"Sica","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"25","key":"2024081315253455200_bib21","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2024081315253455200_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0022-1759(80)90091-5","article-title":"Determination of alternative pathway of complement activity in mouse serum using rabbit erythrocytes","volume":"36","author":"Van Dijk","year":"1980","journal-title":"J\u00a0Immunol Methods"},{"issue":"6","key":"2024081315253455200_bib23","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1111\/j.1523-1755.2005.00742.x","article-title":"Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis","volume":"68","author":"Tanaka","year":"2005","journal-title":"Kidney Int"},{"issue":"9","key":"2024081315253455200_bib24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"issue":"11","key":"2024081315253455200_bib25","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nbt1342","article-title":"Complement-targeted therapeutics","volume":"25","author":"Ricklin","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"17","key":"2024081315253455200_bib26","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood-2011-06-359646","article-title":"Design and development of TT30, a novel C3d-targeted C3\/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases","volume":"118","author":"Fridkis-Hareli","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2024081315253455200_bib27","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.15252\/embj.201593673","article-title":"Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode","volume":"35","author":"Forneris","year":"2016","journal-title":"EMBO J"},{"issue":"4965","key":"2024081315253455200_bib28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1126\/science.2371562","article-title":"Soluble human complement receptor type 1: in\u00a0vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis","volume":"249","author":"Weisman","year":"1990","journal-title":"Science"},{"issue":"2","key":"2024081315253455200_bib29","doi-asserted-by":"crossref","first-page":"100154","DOI":"10.1016\/j.xops.2022.100154","article-title":"A\u00a0phase I, single ascending dose study of GEM103 (recombinant human complement factor H) in patients with geographic atrophy","volume":"2","author":"Khanani","year":"2022","journal-title":"Ophthalmol Sci"},{"issue":"7","key":"2024081315253455200_bib30","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/02713683.2022.2053725","article-title":"A\u00a0novel full-length recombinant human complement factor H (CFH; GEM103) for the treatment of age-related macular degeneration shows similar in\u00a0vitro functional activity to native CFH","volume":"47","author":"Biggs","year":"2022","journal-title":"Curr Eye Res"},{"issue":"11","key":"2024081315253455200_bib31","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.4049\/jimmunol.1203548","article-title":"Rational engineering of a minimized immune inhibitor with unique triple-targeting properties","volume":"190","author":"Schmidt","year":"2013","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"2024081315253455200_bib32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4049\/jimmunol.2300242","article-title":"The complement-targeted inhibitor mini-FH protects against experimental periodontitis via both C3-dependent and C3-independent Mechanisms","volume":"211","author":"Li","year":"2023","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"2024081315253455200_bib33","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4049\/jimmunol.1501919","article-title":"Comparative analysis of novel complement-targeted inhibitors, MiniFH, and the natural regulators factor H and factor H-like protein 1 reveal functional determinants of complement regulation","volume":"196","author":"Harder","year":"2016","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"2024081315253455200_bib34","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1084\/jem.20070432","article-title":"A\u00a0novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis","volume":"204","author":"Katschke","year":"2007","journal-title":"J\u00a0Exp Med"},{"issue":"12","key":"2024081315253455200_bib35","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1172\/JCI17348","article-title":"Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation","volume":"111","author":"Song","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"3-4","key":"2024081315253455200_bib36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jmb.2012.02.038","article-title":"Solution structure of TT30, a novel complement therapeutic agent, provides insight into its joint binding to complement C3b and C3d","volume":"418","author":"Li","year":"2012","journal-title":"J\u00a0Mol Biol"},{"issue":"26","key":"2024081315253455200_bib37","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1182\/blood-2011-12-398792","article-title":"The complement receptor 2\/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment","volume":"119","author":"Risitano","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2024081315253455200_bib38","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.V126.23.2137.2137","article-title":"Safety and pharmacokinetics of the complement inhibitor TT30 in a phase I trial for untreated PNH patients","volume":"126","author":"Risitano","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2024081315253455200_bib39","first-page":"29","article-title":"A\u00a0new function of the activated third component of complement: binding to C5, an essential step for C5 activation","volume":"34","author":"Vogt","year":"1978","journal-title":"Immunology"},{"issue":"3","key":"2024081315253455200_bib40","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.4049\/jimmunol.164.3.1379","article-title":"Functional role of the noncatalytic subunit of complement C5 convertase","volume":"164","author":"Rawal","year":"2000","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"2024081315253455200_bib41","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.str.2009.01.015","article-title":"The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb","volume":"17","author":"Krishnan","year":"2009","journal-title":"Structure"},{"issue":"3","key":"2024081315253455200_bib42","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/emboj.2010.341","article-title":"Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex","volume":"30","author":"Laursen","year":"2011","journal-title":"EMBO J"},{"issue":"8","key":"2024081315253455200_bib43","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2024081315253455200_bib44","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1182\/bloodadvances.2019031591","article-title":"Absence of complement component 3 does not prevent classical pathway-mediated hemolysis","volume":"3","author":"Zhang","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"2024081315253455200_bib45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood.2020005959","article-title":"Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity","volume":"137","author":"Mannes","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2024081315253455200_bib46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21757","article-title":"Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria","volume":"85","author":"Hillmen","year":"2010","journal-title":"Am J Hematol"},{"issue":"11","key":"2024081315253455200_bib47","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ajh.25960","article-title":"C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab","volume":"95","author":"de Castro","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"2024081315253455200_bib48","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024081315253455200_bib49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-3083.2006.01729.x","article-title":"Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H","volume":"63","author":"Reis","year":"2006","journal-title":"Scand J Immunol"},{"issue":"14","key":"2024081315253455200_bib50","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1016\/j.molimm.2009.04.029","article-title":"Complement in human diseases: lessons from complement deficiencies","volume":"46","author":"Botto","year":"2009","journal-title":"Mol Immunol"},{"issue":"4","key":"2024081315253455200_bib51","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J\u00a0Cell Mol Med"},{"key":"2024081315253455200_bib52","first-page":"5","article-title":"Oral Monotherapy with iptacopan, a proximal complement inhibitor of factor B, has superior efficacy to intravenous terminal complement inhibition with standard of care eculizumab or ravulizumab and favorable safety in patients with paroxysmal nocturnal hemoglobinuria and residual anemia: results from the randomized, active-comparator-controlled, open-label, multicenter, phase III Apply-PNH Study","volume":"140","author":"de Latour","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024081315253455200_bib53","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/imr.13138","article-title":"With complements: C3 inhibition in the clinic","volume":"313","author":"Kolev","year":"2023","journal-title":"Immunol Rev"},{"issue":"1","key":"2024081315253455200_bib54","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1038\/s41467-022-33003-7","article-title":"Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors","volume":"13","author":"Lamers","year":"2022","journal-title":"Nat Commun"},{"key":"2024081315253455200_bib55","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3389\/fimmu.2018.01433","article-title":"Alternative pathway is essential for glomerular complement activation and proteinuria in a mouse model of membranous nephropathy","volume":"9","author":"Luo","year":"2018","journal-title":"Front Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/4181\/2237882\/blooda_adv-2024-012874-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/4181\/2237882\/blooda_adv-2024-012874-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:26:20Z","timestamp":1723562780000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/15\/4181\/516507\/CG001-a-C3b-targeted-complement-inhibitor-blocks-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":55,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012874","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]}}}